KINGSWOOD CAPITAL MARKETS
Division of Benchmark Investments, Inc.
17 Battery Place, Suite 625
New York, New York 10004
April 22, 2021
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Attention: Nick Lamparski, Esq.
Re: | Withdrawal of Request for Acceleration of Effective Date Protagenic Therapeutics, Inc. Registration Statement on Form S-l File No. 333-253006 |
Ladies and Gentlemen:
On April 21, 2021, we, as the Representative of the underwriters, filed a letter with the Securities and Exchange Commission via EDGAR requesting, pursuant to Rule 461 under the Securities Act of 1933, as amended, the acceleration of the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-253006) so that it may be declared effective on April 22, 2021, at 5:00 p.m. Eastern Time, or as soon thereafter as practicable. Protagenic Therapeutics, Inc. is no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.
Very truly yours,
KINGSWOOD CAPITAL MARKETS, division of Benchmark Investments, Inc. | ||
By: | /s/ Sam Fleischman | |
Name: | Sam Fleischman | |
Title: | Supervisory Principal |